About Nucleonics
Nucleonics is a company based in Langhorne (United States) founded in 2001 was acquired by Alnylam in December 2008.. Nucleonics has raised $51.9 million across 3 funding rounds from investors including Alnylam, Oxford Finance and Burrill and Company. Nucleonics offers products and services including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology. Nucleonics operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Denali Therapeutics, MiRagen and Avidity Biosciences, among others.
- Headquarter Langhorne, United States
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Nucleonics Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleonics
Nucleonics offers a comprehensive portfolio of products and services, including Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
RNAi-based treatment targeting Hepatitis B virus
RNAi-based treatment for Hepatitis C genotypes
Proprietary system for efficient DNA vector delivery
Funding Insights of Nucleonics
Nucleonics has successfully raised a total of $51.9M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $2.7 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $2.7M
-
First Round
First Round
(01 Apr 2004)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2004 | Amount | Series B - Nucleonics | Valuation |
investors |
|
| Jun, 2004 | Amount | Series B - Nucleonics | Valuation |
investors |
|
| Apr, 2004 | Amount | Series B - Nucleonics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nucleonics
Nucleonics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Oxford Finance and Burrill and Company. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nucleonics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nucleonics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nucleonics Comparisons
Competitors of Nucleonics
Nucleonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Denali Therapeutics, MiRagen and Avidity Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Nucleonics
When was Nucleonics founded?
Nucleonics was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Where is Nucleonics located?
Nucleonics is headquartered in Langhorne, United States. It is registered at Langhorne, Pennsylvania, United States.
Is Nucleonics a funded company?
Nucleonics is a funded company, having raised a total of $51.9M across 3 funding rounds to date. The company's 1st funding round was a Series B of $40.9M, raised on Apr 01, 2004.
What does Nucleonics do?
Nucleonics was a clinical stage company focussed on developing RNAi therapeutics for viral and other diseases. It claims to include over 100 active patent filings, including 16 that have granted worldwide and 6 that have been granted in the U.S., Europe, or Japan. Its lead candidate NUC-B1000 is an RNAi-based therapy which was in phase 2 trials for Hepatitis-B. In December 2008, Alnylam acquired Nucelonics and its assets.
Who are the top competitors of Nucleonics?
Nucleonics's top competitors include Moderna, Juno Therapeutics and Adaptive Biotechnologies.
What products or services does Nucleonics offer?
Nucleonics offers Hepatitis B Therapeutic Program, Hepatitis C Therapeutic Program, and DNA Delivery Technology.
Who are Nucleonics's investors?
Nucleonics has 9 investors. Key investors include Alnylam, Oxford Finance, Burrill and Company, Quaker Partners Management, and SR One.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.